Kim Youdong, Jeon Gyeong Sik, Choi Sun Young, Kim Man Deuk, Lee Shin Jae
Department of Radiology, CHA University School of Medicine, CHA Bundang Medical Center, 59 Yatap-ro, Bundang-gu, Seongnam, Republic of Korea.
Department of Radiology, CHA University School of Medicine, CHA Bundang Medical Center, 59 Yatap-ro, Bundang-gu, Seongnam, Republic of Korea.
Taiwan J Obstet Gynecol. 2017 Aug;56(4):477-481. doi: 10.1016/j.tjog.2016.10.002.
To evaluate the efficacy and safety of sclerotherapy as the treatment of infected postoperative lymphocele in gynecologic malignancy patients.
Percutaneous catheter drainage (PCD) with or without sclerotherapy was performed for postoperative lymphocele in 75 patients from 2002 to 2014. Eighty-eight lymphoceles (43 non-infected as group A, 45 infected as group B) in 75 patients (mean age ± SD; 50.3 ± 11.3) were included. Sclerotherapy was performed in 17 (39.5%, group A-S) lymphoceles in group A and 14 (31.1%, group B-S) in group B. Absolute ethanol was the most frequently used sclerosant (28 of total 36 sessions). Mean follow-up period was 37 months (range: 1-154).
Sclerotherapy was clinically successful in 13 lymphoceles in both group A-S (76.5%) and group B-S (92.9%) without statistical significance. Compared to the pre-sclerotherapy period, group B-S demonstrated significantly decreased drainage volume after sclerotherapy (662.7 ml vs. 100.6 ml, p = 0.019). Group A-S failed to demonstrate significant decrease in drainage volume after sclerotherapy. Recurrence occurred in 4 patients in group A-S and 1 in group B-S, without statistical significance. No major complication was noted.
Sclerotherapy significantly reduces the drainage volume, and might help shorten catheter placement time in infected lymphoceles.
评估硬化治疗作为妇科恶性肿瘤患者术后感染性淋巴囊肿治疗方法的有效性和安全性。
2002年至2014年,对75例术后淋巴囊肿患者进行了经皮导管引流(PCD),其中部分患者联合硬化治疗。纳入75例患者(平均年龄±标准差;50.3±11.3)的88个淋巴囊肿(43个未感染,为A组;45个感染,为B组)。A组17个(39.5%,A-S组)淋巴囊肿和B组14个(31.1%,B-S组)淋巴囊肿接受了硬化治疗。无水乙醇是最常用的硬化剂(共36次治疗,其中28次使用无水乙醇)。平均随访期为37个月(范围:1-154个月)。
硬化治疗在A-S组和B-S组的13个淋巴囊肿中临床成功(分别为76.5%和92.9%),无统计学意义。与硬化治疗前相比,B-S组硬化治疗后引流量显著减少(662.7 ml对100.6 ml,p = 0.019)。A-S组硬化治疗后引流量未显著减少。A-S组4例患者和B-S组1例患者复发,无统计学意义。未观察到严重并发症。
硬化治疗可显著减少引流量,并可能有助于缩短感染性淋巴囊肿的置管时间。